The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease
Open accessAbstract
Parkinson’s disease (PD) usually presents in older adults and typically has both motor and non-motor dysfunctions. PD is a progressive neurodegenerative disorder resulting from dopaminergic neuronal cell loss in the mid-brain substantia nigra pars compacta region. Outlined here is an integrative medicine and health strategy that highlights five treatment options for people with Parkinson’s (PwP): rehabilitate, therapy, restorative, maintenance, and surgery. Rehabilitating begins following the diagnosis and throughout any additional treatment processes, especially vis-à-vis consulting with physical, occupational, and/or speech pathology therapist(s). Therapy uses daily administration of either the dopamine precursor levodopa (with carbidopa) or a dopamine agonist, compounds that preserve residual dopamine, and other specific motor/non-motor-related compounds. Restorative uses strenuous aerobic exercise programs that can be neuroprotective. Maintenance uses complementary and alternative medicine substances that potentially support and protect the brain microenvironment. Finally, surgery, including deep brain stimulation, is pursued when PwP fail to respond positively to other treatment options. There is currently no cure for PD. In conclusion, the best strategy for treating PD is to hope to slow disorder progression and strive to achieve stability with neuroprotection. The ultimate goal of any management program is to improve the quality-of-life for a person with Parkinson’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924 · cited 5×
“Dopamine ag‐ onists are also frequently paired in combination with carbidopa/levodopa, especially as a “bridge” to stabilize the on–off periods PwP may experience on long‐term carbidopa/levo‐ dopa therapy [1,14].”
BackgroundInfluentialNon-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
Chaudhuri, K. R., & Schapira, A. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,738
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
Modification of Parkinsonism — Chronic Treatment with L-Dopa
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902132800701 · Cited by 1,284
Muscle–Organ Crosstalk: The Emerging Roles of Myokines
Severinsen, M. C. K., & Pedersen, B. K. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa016 · Cited by 1,226
Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology
Simon, D. K., Tanner, C. M., & Brundin, P. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.08.002 · Cited by 1,114
Männistö, P. T., & Kaakkola, S. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01423-6 · Cited by 1,068 · cited 1×
“Inhibitors of cathecol-O-methyl transferase (COMT) enzymes prevent the processing of levodopa to 3-O-methyldopa [68,69].”
BackgroundUpdate on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review
Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., Weintraub, D., Sampaio, C., & and the collaborators of the Parkinson's Disease Update on Non‐Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence‐Based Medicine Committee (2019) · Movement Disorders · doi:10.1002/mds.27602 · Cited by 1,007
Fox, S. H., Katzenschlager, R., Lim, S., Barton, B., de Bie, R. M. A., Seppi, K., Coelho, M., Sampaio, C., & on behalf of the Movement Disorder Society Evidence‐Based Medicine Committee (2018) · Movement Disorders · doi:10.1002/mds.27372 · Cited by 1,002
Kordower, J. H., Freeman, T. B., Snow, B. J., Vingerhoets, F. J. G., Mufson, E. J., Sanberg, P. R., Hauser, R. A., Smith, D. A., Nauert, G. M., Perl, D. P., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321702 · Cited by 860
Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease
Petzinger, G. M., Fisher, B. E., McEwen, S., Beeler, J. A., Walsh, J. P., & Jakowec, M. W. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70123-6 · Cited by 798
Physical activity and muscle-brain crosstalk
Pedersen, B. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0174-x · Cited by 772 · cited 1×
“Exercise has been found to promote substances that have been termed ‘exerkines’, shown to influence homeostasis [115,116].”
BackgroundAmantadine in the Treatment of Parkinson's Disease
Schwab, R. S. (1969) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1969.03160070046011 · Cited by 664
THE BIOCHEMISTRY OF PARKINSON'S DISEASE
Cookson, M. R. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133400 · Cited by 664
A Controlled Trial of Rasagiline in Early Parkinson Disease: The TEMPO Study
(2002) · Archives of Neurology · doi:10.1001/archneur.59.12.1937 · Cited by 579
Wright, C. E., Tallan, H. H., Lin, Y. Y., & Gaull, G. E. (1986) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.55.070186.002235 · Cited by 571
van der Kolk, N. M., de Vries, N. M., Kessels, R. P. C., Joosten, H., Zwinderman, A. H., Post, B., & Bloem, B. R. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30285-6 · Cited by 565
Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations
Jankovic, J. (2005) · Movement Disorders · doi:10.1002/mds.20458 · Cited by 547
Schenkman, M., Moore, C. G., Kohrt, W. M., Hall, D. A., Delitto, A., Comella, C. L., Josbeno, D. A., Christiansen, C. L., Berman, B. D., Kluger, B. M., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3517 · Cited by 515
The molecular targets of resveratrol
Kulkarni, S. S., & Cantó, C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.005 · Cited by 477 · cited 1×
“Trans-resveratrol is a potent antioxidant capable of reducing free radicals in the environment of the brain [141,142].”
BackgroundFisher, B. E., Wu, A. D., Salem, G. J., Song, J., Lin, C.-H. (., Yip, J., Cen, S., Gordon, J., Jakowec, M., & Petzinger, G. (2008) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2008.01.013 · Cited by 474
Does vigorous exercise have a neuroprotective effect in Parkinson disease?
Ahlskog, J. E. (2011) · Neurology · doi:10.1212/wnl.0b013e318225ab66 · Cited by 463
Genetics of Parkinson's disease: An introspection of its journey towards precision medicine
Bandres-Ciga, S., Diez-Fairen, M., Kim, J. J., & Singleton, A. B. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104782 · Cited by 370
Paillard, T., Rolland, Y., & de Souto Barreto, P. (2015) · Journal of Clinical Neurology · doi:10.3988/jcn.2015.11.3.212 · Cited by 365
DATATOP: A Multicenter Controlled Clinical Trial in Early Parkinson's Disease: Parkinson Study Group
(1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460028009 · Cited by 354
Doi, D., Magotani, H., Kikuchi, T., Ikeda, M., Hiramatsu, S., Yoshida, K., Amano, N., Nomura, M., Umekage, M., Morizane, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17165-w · Cited by 350
Muscle as a paracrine and endocrine organ
Giudice, J., & Taylor, J. M. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.005 · Cited by 331
The Role of Innate and Adaptive Immunity in Parkinson's Disease
Kannarkat, G. T., Boss, J. M., & Tansey, M. G. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130250 · Cited by 324
A Systematic Review of Beliefs Involved in the Use of Complementary and Alternative Medicine
Bishop, F. L., Yardley, L., & Lewith, G. T. (2007) · Journal of Health Psychology · doi:10.1177/1359105307082447 · Cited by 312
Fisher, B. E., Petzinger, G. M., Nixon, K., Hogg, E., Bremmer, S., Meshul, C. K., & Jakowec, M. W. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20162 · Cited by 311
Clinical spectrum of impulse control disorders in Parkinson’s disease
Weintraub, D., David, A. S., Evans, A. H., Grant, J. E., & Stacy, M. (2015) · Movement Disorders · doi:10.1002/mds.26016 · Cited by 311
Exercise-Induced Neuroplasticity: A Mechanistic Model and Prospects for Promoting Plasticity
El-Sayes, J., Harasym, D., Turco, C. V., Locke, M. B., & Nelson, A. J. (2019) · The Neuroscientist · doi:10.1177/1073858418771538 · Cited by 302
Magnesium Metabolism: A Review
Ebel, H., & Günther, T. (1980) · cclm · doi:10.1515/cclm.1980.18.5.257 · Cited by 291
Elsworth, J. D., & Roth, R. H. (1997) · Experimental Neurology · doi:10.1006/exnr.1996.6379 · Cited by 285
Forced, not voluntary, exercise improves motor function in Parkinson's disease patients
Ridgel, A. L., Vitek, J. L., & Alberts, J. L. (2009) · Neurorehabilitation and neural repair · doi:10.1177/1545968308328726 · Cited by 284
Comparing exercise in Parkinson's disease—the Berlin BIG Study
Ebersbach, G., Ebersbach, A., Edler, D., Kaufhold, O., Kusch, M., Kupsch, A., & Wissel, J. (2010) · Movement Disorders · doi:10.1002/mds.23212 · Cited by 253
Hagen, T. M., Ingersoll, R. T., Wehr, C. M., Lykkesfeldt, J., Vinarsky, V., Bartholomew, J. C., Song, M.-H., & Ames, B. N. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9562 · Cited by 252
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244
Ferretta, A., Gaballo, A., Tanzarella, P., Piccoli, C., Capitanio, N., Nico, B., Annese, T., Di Paola, M., Dell'Aquila, C., De Mari, M., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.02.010 · Cited by 243
Jiang, T.-F., Zhang, Y.-J., Zhou, H.-Y., Wang, H.-M., Tian, L.-P., Liu, J., Ding, J.-Q., & Chen, S.-D. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9431-7 · Cited by 220
Enhancing neuroplasticity in the basal ganglia: The role of exercise in Parkinson's disease
Petzinger, G. M., Fisher, B. E., Van Leeuwen, J., Vukovic, M., Akopian, G., Meshul, C. K., Holschneider, D. P., Nacca, A., Walsh, J. P., & Jakowec, M. W. (2010) · Movement Disorders · doi:10.1002/mds.22782 · Cited by 217
Rascol, O., Fitzer-Attas, C. J., Hauser, R., Jankovic, J., Lang, A., Langston, J. W., Melamed, E., Poewe, W., Stocchi, F., Tolosa, E., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70073-4 · Cited by 212
Exercise and neuroplasticity in persons living with Parkinson's disease.
Hirsch, M. A., & Farley, B. G. (2009) · PubMed · Cited by 209
Dopamine agonist therapy in early Parkinson's disease
Stowe, R., Ives, N., Clarke, C. E., van Hilten, Ferreira, J., Hawker, R. J., Shah, L., Wheatley, K., & Gray, R. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006564.pub2 · Cited by 208
Delaying Brain Mitochondrial Decay and Aging with Mitochondrial Antioxidants and Metabolites
LIU, J., ATAMNA, H., KURATSUNE, H., & AMES, B. N. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb02090.x · Cited by 203
DATATOP: A decade of neuroprotective inquiry
Shoulson, I., & Parkinson Study Group (1998) · Annals of Neurology · doi:10.1002/ana.410440724 · Cited by 201
Characteristics of catechol O-methyltransferase (COMT) and properties of selective COMT inhibitors
Männistö, P. T., Ulmanen, I., Lundstrom, K. H., Taskinen, J., Tenhunen, J., Tilgmann, C., & Kaakkola, S. (1992) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7144-0_9 · Cited by 200
Farley, B. G., & Koshland, G. F. (2005) · Experimental Brain Research · doi:10.1007/s00221-005-0179-7 · Cited by 195
Moderate treadmill exercise prevents oxidative stress-induced anxiety-like behavior in rats
Salim, S., Sarraj, N., Taneja, M., Saha, K., Tejada-Simon, M. V., & Chugh, G. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.12.039 · Cited by 192
Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations
Carbone, F., Djamshidian, A., Seppi, K., & Poewe, W. (2019) · CNS Drugs · doi:10.1007/s40263-019-00661-z · Cited by 190
Clinical development of curcumin in neurodegenerative disease
Hu, S., Maiti, P., Ma, Q., Zuo, X., Jones, M. R., Cole, G. M., & Frautschy, S. A. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1044981 · Cited by 179
Fox, C., Ebersbach, G., Ramig, L., & Sapir, S. (2012) · Parkinson's Disease · doi:10.1155/2012/391946 · Cited by 178 · cited 1×
“While there are other programs that provide similar assistance, LSVT‐LOUD [43–45] and LSVT‐BIG [31,46–48] pioneered these programs spe‐ cifically to help rehabilitate PwP [49].”
BackgroundMobilizing Parkinson’s Disease: The Future of Exercise
Ellis, T., & Rochester, L. (2018) · Journal of Parkinson’s Disease · doi:10.3233/jpd-181489 · Cited by 177
Carapellotti, A. M., Stevenson, R., & Doumas, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236820 · Cited by 173
Che, Y., Hou, L., Sun, F., Zhang, C., Liu, X., Piao, F., Zhang, D., Li, H., & Wang, Q. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0468-2 · Cited by 172
Rafferty, M. R., Schmidt, P. N., Luo, S., Li, K., Marras, C., Davis, T. L., Guttman, M., Cubillos, F., Simuni, T., & on behalf of all NPF-QII Investigators (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-160912 · Cited by 169
Johnstone, D. M., Moro, C., Stone, J., Benabid, A.-L., & Mitrofanis, J. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00500 · Cited by 168
Melatonin and Parkinson's Disease
Mayo, J. C., Sainz, R. M., Tan, D.-X., Antolín, I., Rodríguez, C., & Reiter, R. J. (2005) · Endocrine · doi:10.1385/endo:27:2:169 · Cited by 162
Exercise therapy for Parkinson's disease
Palmer, S. S., Mortimer, J. A., Webster, D. D., Bistevins, R., & Dickinson, G. L. (1986) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/0003-9993(86)90007-9 · Cited by 158
Kurtis, M. M., Rajah, T., Delgado, L. F., & Dafsari, H. S. (2017) · npj Parkinson's Disease · doi:10.1038/npjparkd.2016.24 · Cited by 158
Shoulson, I. (1998) · PubMed · Cited by 154
Monti, D., Zabrecky, G. P., Kremens, D. E., Liang, T., Wintering, N., Cai, J., Wei, X., Bazzan, A. J., Li, Z., Bowen, B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157602 · Cited by 152
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
McFarthing, K., Buff, S., Rafaloff, G., Dominey, T., Wyse, R. K. H., & Stott, S. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202128 · Cited by 149
Interleukin-13 drives metabolic conditioning of muscle to endurance exercise
Knudsen, N. H., Stanya, K. J., Hyde, A. L., Chalom, M. M., Alexander, R. K., Liou, Y.-H., Starost, K. A., Gangl, M. R., Jacobi, D., Liu, S., et al. (2020) · Science · doi:10.1126/science.aat3987 · Cited by 139 · cited 1×
“One recently described exerkine is interleukin-13 (IL-13), which is produced in mouse skeletal tissue and increases with exercise [117,118].”
BackgroundUnrecognized vitamin D 3 deficiency is common in Parkinson disease
Ding, H., Dhima, K., Lockhart, K. C., Locascio, J. J., Hoesing, A. N., Duong, K. T., Lipsanopoulos, A. T. T., Hayes, M. T., Sohur, U. S., Wills, A.-M. A., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a95818 · Cited by 137
Are the neuroprotective effects of exercise training systemically mediated?
Tari, A. R., Norevik, C. S., Scrimgeour, N. R., Kobro‐Flatmoen, A., Storm‐Mathisen, J., Bergersen, L. H., Wrann, C. D., Selbæk, G., Kivipelto, M., Moreira, J. B. N., et al. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.02.003 · Cited by 137
Physical Exercise For Parkinson’s Disease: Clinical And Experimental Evidence
de Carvalho, A. O., Filho, A. S. S., Murillo‐Rodríguez, E., Rocha, N., Carta, M. G., & Machado, S. E. D. C. (2018) · Clinical Practice and Epidemiology in Mental Health · doi:10.2174/1745017901814010089 · Cited by 136
Wang, X., Zhang, Z., Zhang, M., Sun, M.-X., Wang, W., & Xie, C. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-1922-x · Cited by 133
Psychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms
Naasan, G., Shdo, S. M., Morenas‐Rodríguez, E., Spina, S., Grinberg, L. T., López, L., Karydas, A., Seeley, W. W., Miller, B. L., & Rankin, K. P. (2020) · Brain · doi:10.1093/brain/awaa413 · Cited by 131
Clozapine in the treatment of tremor
Pakkenberg, H., & Pakkenberg, B. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1986.tb03279.x · Cited by 129
Effects of Exercise on Non-motor Symptoms in Parkinson’s Disease
Amara, A. W., & Memon, A. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.11.004 · Cited by 127
Progressive Resistance Exercise and Parkinson's Disease: A Review of Potential Mechanisms
David, F. J., Rafferty, M. R., Robichaud, J. A., Prodoehl, J., Kohrt, W. M., Vaillancourt, D. E., & Corcos, D. M. (2011) · Parkinson s Disease · doi:10.1155/2012/124527 · Cited by 125
Berganzo, K., Tijero, B., González-Eizaguirre, A., Somme, J. H., Lezcano, E., Gabilondo, I., Fernández, M., Zarranz, J. J., & Gómez‐Esteban, J. C. (2014) · Neurología · doi:10.1016/j.nrl.2014.10.010 · Cited by 124
Berganzo, K., Tijero, B., González-Eizaguirre, A., Somme, J. H., Lezcano, E., Gabilondo, I., Fernandez, M., Zarranz, J. J., & Gómez‐Esteban, J. C. (2016) · Neurología (English Edition) · doi:10.1016/j.nrleng.2014.10.016 · Cited by 124
Lees, A. J., TOLOSA, E. S., & Olanow, C. W. (2014) · Movement Disorders · doi:10.1002/mds.26120 · Cited by 119
International validation of a behavioral scale in Parkinson's disease without dementia
Rieu, I., Martínez‐Martín, P., Pereira, B., de Chazeron, I., Metman, L. V., Jahanshahi, M., Ardouin, C., Chéreau, I., Brefel‐Courbon, C., Ory‐Magne, F., et al. (2015) · Movement Disorders · doi:10.1002/mds.26223 · Cited by 115
Emotional manifestations of PD: Neurobiological basis
Castrioto, A., Thobois, S., Carnicella, S., Maillet, A., & Krack, P. (2016) · Movement Disorders · doi:10.1002/mds.26587 · Cited by 110
Abbott, A. (2010) · Nature · doi:10.1038/466s6a · Cited by 109
Clozapine‐responsive tremor in Parkinson's disease
Friedman, J. H., & Lannon, M. C. (1990) · Movement Disorders · doi:10.1002/mds.870050307 · Cited by 109
Jang, Y., Koo, J., Kwon, I., Kang, E., Um, H.-S., Soya, H., Lee, Y., & Cho, J. (2016) · Brain Research · doi:10.1016/j.brainres.2016.10.029 · Cited by 107
Memory, Mood, and Vitamin D in Persons with Parkinson's Disease
Peterson, A. L., Murchison, C., Zabetian, C. P., Leverenz, J. B., Watson, G. S., Montine, T. J., Carney, N., Bowman, G. L., Edwards, K. L., & Quinn, J. F. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-130206 · Cited by 106
Apathy and Impulse Control Disorders: Yin & Yang of Dopamine Dependent Behaviors
Sierra, M., Carnicella, S., Strafella, A. P., Bichon, A., Lhommée, E., Castrioto, A., Chabardès, S., Thobois, S., & Krack, P. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150535 · Cited by 106
Przuntek, H., Conrad, B., DICHGANS, J., Kraus, P. H., Krauseneck, P., Pergande, G., Rinne, U. K., Schimrigk, К., Schnitker, J., & Vogel, H. P. (1999) · European Journal of Neurology · doi:10.1111/j.1468-1331.1999.tb00007.x · Cited by 106
Surgical Treatment of Parkinson's Disease: Devices and Lesion Approaches
Sharma, V. D., Patel, M., & Miocinovic, S. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00939-x · Cited by 105
Farley, B. G., Fox, C., Ramig, L. O., & McFarland, D. H. (2008) · Topics in Geriatric Rehabilitation · doi:10.1097/01.tgr.0000318898.87690.0d · Cited by 99
Zhou, W., Barkow, J. C., & Freed, C. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0190160 · Cited by 99
Lamotte, G., Rafferty, M. R., Prodoehl, J., Kohrt, W. M., Comella, C. L., Simuni, T., & Corcos, D. M. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-140425 · Cited by 98
Gastrointestinal Dysfunction in Parkinson’s Disease
Skjærbæk, C., Knudsen, K., Horsager, J., & Borghammer, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030493 · Cited by 96
Palasz, E., Niewiadomski, W., Gasiorowska, A., Wysocka, A., Stepniewska, A., & Niewiadomska, G. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01143 · Cited by 95
MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?
Foley, P., Gerlach, M., Youdim, M. B. H., & Riederer, P. F. (2000) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(99)00043-7 · Cited by 93
Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia
Perez‐Lloret, S., & Rascol, O. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1869-1 · Cited by 93
Hribar, C. A., Cobbold, P. H., & Church, F. (2020) · Brain Sciences · doi:10.3390/brainsci10050284 · Cited by 93
Self-citationOldfield, V., Keating, G. M., & Perry, C. M. (2007) · Drugs · doi:10.2165/00003495-200767120-00006 · Cited by 92
Cognitive decline: A vitamin B perspective
Mikkelsen, K., Stojanovska, L., Tangalakis, K., Bosevski, M., & Apostolopoulos, V. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.08.001 · Cited by 92
Deep Brain Stimulation Selection Criteria for Parkinson’s Disease: Time to Go beyond CAPSIT-PD
Artusi, C. A., Lopiano, L., & Morgante, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123931 · Cited by 92
The Role of Vitamin D in Disease Progression in Early Parkinson’s Disease
Sleeman, I. J., Aspray, T., Lawson, R. A., Coleman, S. Y., Duncan, G. W., Khoo, T. K., Schoenmakers, I., Rochester, L., Burn, D. J., & Yarnall, A. J. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171122 · Cited by 89
Katz, M., Won, S. J., Park, Y. H., Orr, A., Jones, D. P., Swanson, R. A., & Glass, G. A. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.02.020 · Cited by 87
Long-term outcomes following deep brain stimulation for Parkinson’s disease
Hitti, F. L., Ramayya, A. G., McShane, B., Yang, A. I., Vaughan, K. A., & Baltuch, G. H. (2019) · Journal of neurosurgery · doi:10.3171/2018.8.jns182081 · Cited by 85
Stress and mindfulness in Parkinson’s disease – a survey in 5000 patients
van der Heide, A., Speckens, A. E. M., Meinders, M. J., Rosenthal, L. S., Bloem, B. R., & Helmich, R. C. (2021) · npj Parkinson's Disease · doi:10.1038/s41531-020-00152-9 · Cited by 82 · cited 1×
“Stress and mindfulness studies are beginning to demonstrate that being mindful can substantially benefit PwP [108,109].”
BackgroundStress and Mindfulness in Parkinson's Disease: Clinical Effects and Potential Underlying Mechanisms
van der Heide, A., Meinders, M. J., Speckens, A. E. M., Peerbolte, T. F., Bloem, B. R., & Helmich, R. C. (2021) · Movement Disorders · doi:10.1002/mds.28345 · Cited by 80 · cited 1×
“Stress and mindfulness studies are beginning to demonstrate that being mindful can substantially benefit PwP [108,109].”
BackgroundAn Alternative Medicine Treatment for Parkinson's Disease: Results of a Multicenter Clinical Trial
HP-200 in Parkinson's Disease Study Group (1995) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.1995.1.249 · Cited by 79
Zhang, J., Wang, X., Feng, Y., Fekete, R., Jankovic, J. J., & Wu, Y. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.635494 · Cited by 78
A Review of the Clinical Evidence for Complementary and Alternative Therapies in Parkinson’s Disease
Bega, D., González-Latapí, P., Zadikoff, C., & Simuni, T. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-014-0314-5 · Cited by 77
Silveira, C. R. A., Roy, É., Intzandt, B., & Almeida, Q. J. (2018) · Brain and Cognition · doi:10.1016/j.bandc.2018.01.002 · Cited by 77
Crowley, E. K., Nolan, Y. M., & Sullivan, A. M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.11.003 · Cited by 76
Yuan, F., Guo, X., Wei, X., Xie, F. X., Zheng, J., Huang, Y., Huang, Z.-H., Chang, Z., Li, H.-X., Guo, Y., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14399 · Cited by 75
Sacheli, M., Murray, D., Vafai, N. M., Cherkasova, M. V., Dinelle, K., Shahinfard, E., Neilson, N., McKenzie, J., Schulzer, M., Appel‐Cresswell, S., et al. (2018) · Movement Disorders · doi:10.1002/mds.27498 · Cited by 74
Lamotte, G., Rafferty, M. R., Prodoehl, J., Kohrt, W. M., Comella, C. L., Simuni, T., & Corcos, D. M. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-159002 · Cited by 69
Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study
Olanow, C. W., for the 006 study group, Espay, A. J., Stocchi, F., Ellenbogen, A. L., Leinonen, M., Adar, L., Case, R. J., Orenbach, S. F., Yardeni, T., et al. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202285 · Cited by 69
Optimal Treatment of Depression and Anxiety in Parkinson's Disease
Pontone, G. M., & Mills, K. A. (2021) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2021.02.037 · Cited by 67
The changing landscape of surgery for Parkinson's Disease
Lozano, C. S., Tam, J., & Lozano, A. M. (2017) · Movement Disorders · doi:10.1002/mds.27228 · Cited by 66
Rafferty, M. R., Prodoehl, J., Robichaud, J. A., David, F. J., Poon, C., Goelz, L. C., Vaillancourt, D. E., Kohrt, W. M., Comella, C. L., & Corcos, D. M. (2016) · Neurology Report · doi:10.1097/npt.0000000000000163 · Cited by 65
Ebersbach, G., Grust, U., Ebersbach, A., Wegner, B., Gandor, F., & Kühn, A. A. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1245-8 · Cited by 58
Hou, L., Che, Y., Sun, F., & Wang, Q. (2018) · Amino Acids · doi:10.1007/s00726-018-2547-1 · Cited by 52
Hamilton, C. L., Khoury, H. E., Hamilton, D. J., Nicklason, F., & Mitrofanis, J. (2019) · Photobiomodulation Photomedicine and Laser Surgery · doi:10.1089/photob.2019.4663 · Cited by 52
Thiamine and Parkinson's disease
Lương, K. V. Q., & Nguyễn, L. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.02.008 · Cited by 51
Parkinson's disease is a neuropsychiatric disorder.
Agid, Y., Arnulf, I., Bejjani, P.-B., Bloch, F., Bonnet, A. M., Damier, P., Dubois, B., François, C., Houéto, J., Iacono, D., et al. (2003) · PubMed · Cited by 50
Management of the aging risk factor for Parkinson's disease
Phillipson, O. T. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.073 · Cited by 49
Ferrazzoli, D., Ortelli, P., Cucca, A., Bakdounes, L., Canesi, M., & Volpe, D. (2020) · Neurodegenerative Disease Management · doi:10.2217/nmt-2019-0025 · Cited by 48
New awakenings: current understanding of sleep dysfunction and its treatment in Parkinson’s disease
Keir, L. H. M., & Breen, D. P. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09651-z · Cited by 46
Neurogenic Orthostatic Hypotension. Lessons From Synucleinopathies
Idiaquez, J. F., Idiaquez, J. F., Casar, J. C., & Biaggioni, I. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa131 · Cited by 44
Ebersbach, G., Grust, U., Ebersbach, A., Wegner, B., Gandor, F., & Kühn, A. A. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1264-5 · Cited by 43
Impact of Mood and Behavioral Disorders on Quality of Life in Parkinson’s disease
Rieu, I., Houeto, J. L., Pereira, B., de Chazeron, I., Bichon, A., Chéreau, I., Ulla, M., Brefel‐Courbon, C., Ory‐Magne, F., Dujardin, K., et al. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-150747 · Cited by 42
Chen, W., Wang, H., Shang, N. N., Liu, J., Li, J., Tang, D. H., & Li, Q. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.055 · Cited by 41
Long-term Parkinson’s disease quality of life after staged DBS: STN vs GPi and first vs second lead
Cernera, S., Eisinger, R. S., Wong, J. K., Ho, K. W. D., Lopes, J. L., To, K., Carbunaru, S., Ramirez‐Zamora, A., Almeida, L., Foote, K. D., et al. (2020) · npj Parkinson s Disease · doi:10.1038/s41531-020-0115-3 · Cited by 41
Magnesium in the CNS: recent advances and developments.
Vink, R. (2016) · PubMed · doi:10.1684/mrh.2016.0408 · Cited by 40
Shen, Y., Dai, L., Tian, H., Xu, R., Li, F., Li, Z., Zhou, J., Wang, L., Dong, J., & Sun, L. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s230688 · Cited by 40
Bryans, L., Palmer, A. D., Anderson, S., Schindler, J. S., & Graville, D. J. (2020) · Journal of Communication Disorders · doi:10.1016/j.jcomdis.2020.106031 · Cited by 40
Dallapiazza, R. F., Vloo, P. D., Fomenko, A., Lee, D. J., Hamani, C., Munhoz, R. P., Hodaie, M., Lozano, A. M., Fasano, A. A., & Kalia, S. K. (2018) · Codon Publications eBooks · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch8 · Cited by 34
Ciurleo, R., Corallo, F., Bonanno, L., Buono, V. L., Lorenzo, G. D., Versaci, R., Allone, C., Palmeri, R., Bramanti, P., & Marino, S. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8951-3 · Cited by 33
Schenkman, M., Moore, C. G., Kohrt, W. M., Hall, D. A., Delitto, A., Comella, C. L., Josbeno, D. A., Christiansen, C. L., Berman, B. D., Kluger, B. M., et al. (2018) · NORA - Norwegian Open Research Archives · Cited by 33
The Mechanism of Physical Activity-induced Amelioration of Parkinson’s Disease: A Narrative Review
Gronek, P., Haas, A. N., Czarny, W., Podstawski, R., Delabary, M. D. S., Clark, C. C. T., Boraczyński, M., Tarnas, M., Wycichowska, P., Pawlaczyk, M., et al. (2021) · Aging and Disease · doi:10.14336/ad.2020.0407 · Cited by 32
Cheaper, Simpler, and Better: Tips for Treating Seniors With Parkinson Disease
Ahlskog, J. E. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0443 · Cited by 26
Johansson, H., Freidle, M., Ekman, U., Schalling, E., Leavy, B., Svenningsson, P., Hagströmer, M., & Franzén, E. (2020) · Parkinson s Disease · doi:10.1155/2020/2410863 · Cited by 23
Mechanisms Responsible for the High Sensitivity of Neural Cells to Vitamin B1 Deficiency
IuM, P., Pavlova, A. S., & Mezhenska, O. A. (2016) · Neurophysiology · doi:10.1007/s11062-017-9620-3 · Cited by 22
Hall, M.-F. E., & Church, F. (2020) · Brain Sciences · doi:10.3390/brainsci10090612 · Cited by 22
Self-citationEvidence-Based Recommendations for the Oral Health of Patients with Parkinson’s Disease
Martimbianco, A. L. C., Prosdócimi, F. C., Anauate-Netto, C., Santos, E. M., Mendes, G. D., & Fragoso, Y. D. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00237-4 · Cited by 22
Integrative Medicine and Health Therapy for Parkinson Disease
Hall, M.-F. E., & Church, F. (2020) · Topics in Geriatric Rehabilitation · doi:10.1097/tgr.0000000000000278 · Cited by 21
Self-citationPelvic Floor Health in Women with Parkinson’s Disease
Gupta, A., LaFaver, K., Duque, K. R., Lingaiah, A., Meriwether, K. V., Gaskins, J., Gomes, J., Espay, A. J., & Mahajan, A. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202491 · Cited by 13
Vigorous Aerobic Exercise in the Management of Parkinson Disease: A Systematic Review
Rodríguez, M. Á., Albillos‐Almaraz, L., López‐Aguado, I., Crespo, I., Soto, M. D. V., & Olmedillas, H. (2020) · PM&R · doi:10.1002/pmrj.12500 · Cited by 12
Exercise as therapy for Parkinson's?
Crowley, E. K., Nolan, Y. M., & Sullivan, A. M. (2018) · Aging · doi:10.18632/aging.101503 · Cited by 8
Editorial: Integrative Approach to Parkinson's Disease
Kim, S., Wang, X., & Park, H. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00339 · Cited by 8
Ahlskog, J. (2020) · Mayo Clinic proceedings · doi:10.1016/j.mayocp.2020.02.006 · Cited by 8
Disease progression and phenotypes of non‐motor symptoms in Parkinson’s disease
Osaki, Y., Morita, Y., Miyamoto, Y., Furushima, T., Furuta, K., & Furuya, H. (2020) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.12468 · Cited by 8
Non-motor Symptoms in Parkinson’s Disease
Vuletić, V. (2020) · Springer eBooks · doi:10.1007/978-3-030-38606-1_9 · Cited by 7
Exercised cytokines promote endurance
Correia, J. C., & Ruas, J. L. (2020) · Science · doi:10.1126/science.abb4116 · Cited by 5
Inhibition of Aging in Parkinson's Disease: A Case Study
Phillipson, O. T. (2013) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2012.1014 · Cited by 3
Not only loud but also intelligible
Foltynie, T., & Grover, T. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100456 · Cited by 3
Treatment Patterns With Antipsychotics in Long-Term Care Patients With Parkinson’s Disease Psychosis
Rashid, N., Shim, A., Andes, S., Quale, S., & Abler, V. (2021) · Journal of Applied Gerontology · doi:10.1177/0733464820987032 · Cited by 3
Hypotension: A comprehensive review
Bhalke, R. D., Giri, M. A., Anil, R. Y., Balasaheb, N. M., Nanasaheb, P. A., & Pande, V. V. (2021) · Journal of Pharmacognosy and Phytochemistry · Cited by 2
Editorial overview: Muscle and bone are highly effective communicators
Taylor, J. M. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.11.005 · Cited by 1
Neurological Emergencies from Prescription Drugs
Braksick, S. A., & Nasr, D. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-28072-7_16 · Cited by 1
Research works printed but not linked: 6
- Ahlskog, J.E. (2015). The New Parkinson’s Disease Treatment Book: Partnering with Your Doctor to Get the Most from Your Medications, Oxford University Press.
- Santens, 2003, The pathophysiology of motor symptoms in Parkinson’s disease, Acta Neurol. Belg., 103, 129
- Pickut, 2020, Integrative medicine and Parkinson’s disease, Integr. Neurol., 7, 141, 10.1093/med/9780190051617.003.0007 · doi:10.1093/med/9780190051617.003.0007
- Ellenbogen, A., Stocchi, F., Espay, A., Poewe, W., Oren, S., Case, R., and Olanow, C.W. (2021). Impact of Subcutaneous Levodopa Infusion with ND0612 on Patient Reported Outcomes (4506). Neurology, 94. · doi:10.1212/wnl.94.15_supplement.4506
- Hariz, 2017, My 25 Stimulating years with DBS in Parkinson’s disease, J. Parkinson’s Dis., 7, S33, 10.3233/JPD-179007 · DOI
- Stone, J., Johnstone, D., and Mitrofanis, J. (2012, January 28–30). The helmet experiment in Parkinson’s disease: An observation of the mechanism of neuroprotection by near infra-red light. Proceedings of the 9th WALT Congress, Gold Coast, QLD, Australia.
Cited by
Gupta, R., Kumari, S., Senapati, A., Ambasta, R. K., & Kumar, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102013 · Cited by 134
Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · doi:10.20944/preprints202506.2099.v2 · Cited by 57
Christodoulou, D., Reeves, S., Carvalho, N. P., Stellman, J., & Gould, R. L. (2025) · Clinical Gerontologist · doi:10.1080/07317115.2025.2511957 · Cited by 4
“Contemporary approaches to the management of PD aims to holi-stically address non-motor as well as motor symptoms (Pfeiffer, 2016) through pharmacological and, increasingly, psychological interventions (Church, 2021).”
Metadata
- Authors
- Church, F. C.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2021-04-20
- Volume
- 11
- Issue
- 4
- Pages
- 612
- ISSN
- 2218-273X (ISSN-L)
- OpenAlex
- W3155660346
- Cited by
- 290
- References
- 157
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.